Weight Loss, drugs
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Some of the most common peptides for weight loss are glucagon-like peptide 1 (GLP-1) receptor agonists. They include semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound).
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Jessica DeBenedetto has only been on compounded tirzepatide for a ... generic version of the weight-loss drug after her insurer refused to cover Zepbound, the brand-name version made by Eli ...
GLP-1RAs have shown considerable effects for weight loss to treat obesity. A recent Phase 3 trial published in Nature Medicine found that tirzepatide led to additional ... have a 20% reduction ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback